Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-07-07 @ 7:37 PM
Study NCT ID:
NCT07432594
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-25
First Post:
2026-02-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2025-I2M-C&T-B-065
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |